Literature DB >> 31395145

Key Principles of Antiretroviral Pharmacology.

Brandon Dionne1.   

Abstract

Antiretroviral therapy has advanced significantly since zidovudine was first approved. Although 31 antiretrovirals have been approved by the FDA, only about half of those are commonly used. Newer, more tolerable agents have made human immunodeficiency virus into a chronic condition, which can be managed with medication. The most common antiretroviral regimens consist of 2 nucleoside reverse transcriptase inhibitors plus a third agent, often an integrase inhibitor because of better tolerability and fewer drug interactions than other regimens. Understanding the dosage forms, adverse effects, and drug interactions of antiretrovirals allow clinicians to choose the most appropriate regimen for their patient. New developments, such as branded generic regimens and long-acting intramuscular injections, may play a larger role in the future.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antiretroviral; Drug interactions; HIV; Pharmacokinetics; Pharmacology

Mesh:

Substances:

Year:  2019        PMID: 31395145     DOI: 10.1016/j.idc.2019.05.006

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  7 in total

Review 1.  Structure, function, and inhibitor targeting of HIV-1 Nef-effector kinase complexes.

Authors:  Ryan P Staudt; John J Alvarado; Lori A Emert-Sedlak; Haibin Shi; Sherry T Shu; Thomas E Wales; John R Engen; Thomas E Smithgall
Journal:  J Biol Chem       Date:  2020-08-29       Impact factor: 5.157

2.  Inhibitors of HIV-1 Nef-Mediated Activation of the Myeloid Src-Family Kinase Hck Block HIV-1 Replication in Macrophages and Disrupt MHC-I Downregulation.

Authors:  Lori A Emert-Sedlak; Omar Moukha-Chafiq; Haibin Shi; Shoucheng Du; John J Alvarado; Vibha Pathak; Samuel G Tanner; Robert N Hunter; Miranda Nebane; Li Chen; Tatiana V Ilina; Rieko Ishima; Sixue Zhang; Yury V Kuzmichev; Elizabeth R Wonderlich; Susan M Schader; Corinne E Augelli-Szafran; Roger G Ptak; Thomas E Smithgall
Journal:  ACS Infect Dis       Date:  2022-01-05       Impact factor: 5.578

3.  Aspartic peptidase of Phialophora verrucosa as target of HIV peptidase inhibitors: blockage of its enzymatic activity and interference with fungal growth and macrophage interaction.

Authors:  Marcela Q Granato; Ingrid S Sousa; Thabatta L S A Rosa; Diego S Gonçalves; Sergio H Seabra; Daniela S Alviano; Maria C V Pessolani; André L S Santos; Lucimar F Kneipp
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

Review 4.  Pharmacokinetic drug interactions of integrase strand transfer inhibitors.

Authors:  Chi-Hua Lu; Edward M Bednarczyk; Linda M Catanzaro; Alyssa Shon; Jia-Chen Xu; Qing Ma
Journal:  Curr Res Pharmacol Drug Discov       Date:  2021-08-08

Review 5.  Advances in Liver Transplantation for Persons with Human Immunodeficiency Infection.

Authors:  Rebecca N Kumar; Valentina Stosor
Journal:  Curr Infect Dis Rep       Date:  2022-03-15       Impact factor: 3.663

Review 6.  Antiretroviral Drug Discovery Targeting the HIV-1 Nef Virulence Factor.

Authors:  Lori A Emert-Sedlak; Haibin Shi; Colin M Tice; Li Chen; John J Alvarado; Sherry T Shu; Shoucheng Du; Catherine E Thomas; Jay E Wrobel; Allen B Reitz; Thomas E Smithgall
Journal:  Viruses       Date:  2022-09-13       Impact factor: 5.818

7.  Identification of an Antiretroviral Small Molecule That Appears To Be a Host-Targeting Inhibitor of HIV-1 Assembly.

Authors:  Jonathan C Reed; Dennis Solas; Anatoliy Kitaygorodskyy; Beverly Freeman; Dylan T B Ressler; Daryl J Phuong; J Victor Swain; Kent Matlack; Clarence R Hurt; Vishwanath R Lingappa; Jaisri R Lingappa
Journal:  J Virol       Date:  2021-01-13       Impact factor: 5.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.